Beta Bionics, Inc. (BBNX) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	127.3M	100.3M	65.1M	12.0M	179.0K
Cost of Revenue	52.7M	44.7M	29.2M	5.7M	—
Gross Profit	74.6M	55.5M	35.9M	6.3M	179.0K
Operating Expenses
R&D Expense	42.7M	34.8M	26.2M	17.9M	31.4M
SG&A Expense	124.5M	92.4M	55.0M	24.2M	33.5M
General & Admin Expense	37.7M	31.0M	17.9M	12.2M	24.7M
Selling & Marketing Expense	86.8M	61.4M	37.1M	12.0M	8.8M
Other Expenses	—	—	—	—	1.1M
Total Operating Expenses	167.2M	127.2M	81.1M	42.2M	66.0M
Cost and Expenses	219.8M	171.9M	110.4M	47.8M	66.0M
Operating Income (EBIT)	(92.6M)	(71.7M)	(45.3M)	(35.9M)	(65.8M)
Non-Operating
Interest Income	9.5M	10.9M	3.9M	1.8M	196.0K
Interest Expense	—	—	—	—	14.0K
Net Interest Income	9.5M	10.9M	3.9M	1.8M	182.0K
Other Non-Op Income/Expense	9.5M	(1.5M)	(9.5M)	(8.2M)	1.1M
Non-Operating Income (excl Interest)	(5.0M)	1.5M	9.5M	8.2M	(1.1M)
EBT (Pre-Tax Income)	(83.1M)	(73.2M)	(54.8M)	(44.1M)	(64.8M)
Income Tax Expense	—	—	—	—	—
Bottom Line
Net Income	(83.1M)	(73.2M)	(54.8M)	(44.1M)	(64.8M)
Earnings from Cont. Ops	(83.1M)	(73.2M)	(54.8M)	(44.1M)	(64.8M)
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(83.1M)	(73.2M)	(54.8M)	(44.1M)	(64.8M)
Per Share
Basic EPS	($1.87)	($1.81)	($1.28)	($1.03)	($1.51)
Diluted EPS	($1.87)	($1.81)	($1.28)	($1.03)	($1.51)
Revenue Per Share	$2.73	$2.47	$1.52	$0.28	$0.00
Shares
Basic Shares Outstanding	46.5M	40.5M	42.9M	42.9M	42.9M
Diluted Shares Outstanding	46.5M	40.5M	42.9M	42.9M	42.9M
Profitability Metrics
EBITDA	(83.2M)	(70.3M)	(52.5M)	(42.0M)	(62.7M)
D&A	4.3M	2.9M	2.3M	2.1M	2.1M
EBIT	(87.5M)	(73.2M)	(54.8M)	(44.1M)	(64.7M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026